pancreatic cancer

3 curated biomarkers

← Back to browse

FDA-approved treatments

BRCA1
- Lynparza (olaparib) [fda]
- Talzenna (talazoparib) [fda]
BRCA2
- Lynparza (olaparib) [fda]
- Talzenna (talazoparib) [fda]
KRAS
- Krazati (adagrasib) [fda]
- Lumakras (sotorasib) [fda]

Prevalence

BRCA1
Pathogenic germline BRCA1 variants are found in approximately 5% of unselected breast cancers and up to 15% of ovarian cancers.[fda]
BRCA2
Pathogenic germline BRCA2 variants are found in approximately 5% of unselected breast cancers and are also associated with elevated risk of ovarian, pancreatic, and prostate cancer.[fda]
KRAS
KRAS mutations occur in approximately 25% of NSCLC and up to 45% of colorectal cancers; KRAS G12C specifically accounts for approximately 13% of NSCLC and 3%-4% of colorectal cancer cases.[fda]

Tests / detection method

BRCA1
germline genetic testing, somatic NGS
BRCA2
germline genetic testing, somatic NGS
KRAS
NGS

Therapeutic pipeline

BRCA1
- Next-generation PARP1-selective inhibitors [fda]
BRCA2
- Next-generation PARP1-selective inhibitors [fda]
KRAS
- KRAS G12D and pan-RAS/multi-RAS inhibitors (KRAS G12D, KRAS G12V) [fda]

PubMed Central · Oct 1, 2026
Clinical Impact of the C-Reactive Protein-Albumin-Lymphocyte Index as a Prognostic Biomarker in Patients With Recurrent Pancreatic Cancer.
Read at PubMed Central
PubMed Central · Oct 1, 2026
Perioperative Nutritional Changes Predict Adjuvant S-1 Dose Intensity in Resectable Pancreatic Cancer.
Read at PubMed Central
PubMed Central · Sep 4, 2026
Synthetic long peptide and DNA personalized cancer vaccines induce robust neoantigen-specific T cell responses in pancreatic cancer.
Read at PubMed Central
PubMed Central · Sep 2, 2026
[(177)Lu]Lu-AKIR001 for CD44v6-Positive Pancreatic Cancer: Preclinical Efficacy and Combination Strategies.
Read at PubMed Central
PubMed Central · Sep 2, 2026
KRAS is required for plexiform neurofibroma formation and represents a targetable vulnerability in established tumors.
- KRAS (biomarker)
Read at PubMed Central
PubMed Central · Sep 2, 2026
Multinucleated Giant Cells in Human Pancreatic Cancer Are a Distinct Macrophage Population Undergoing a DNA Damage Response and Associated with an Aggressive Tumor Microenvironment.
Read at PubMed Central
PubMed Central · Sep 2, 2026
KRAS Inhibitor-Induced Cancer Cell Death Enhances Sensitivity to Immune-Mediated Bystander Killing of Drug-Resistant Subclones.
- KRAS (biomarker)
Read at PubMed Central
PubMed Central · Sep 2, 2026
Aerobic Exercise Activates S1PR1 Signaling in Tumor Endothelial Cells to Promote Vascular Function in Pancreatic Cancer.
Read at PubMed Central
PubMed Central · Sep 1, 2026
The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial.
- BRCA1 (biomarker)
- BRCA2 (biomarker)
Read at PubMed Central
PubMed Central · Sep 1, 2026
Cardiovascular-Kidney-Metabolic Syndrome Severity and Risk of Pancreatic Cancer in a Large Prospective Cohort.
Read at PubMed Central
PubMed Central · Sep 1, 2026
Dietary-Derived Corchorus olitorius L. Extract Suppresses KRAS-Mutant Pancreatic Cancer by Activating Ferritinophagy-Dependent Ferroptosis.
- KRAS (biomarker)
Read at PubMed Central
PubMed Central · Sep 1, 2026
Artificial Intelligence-Estimated Intrapancreatic Fat and Its Relationship to Familial and Germline Pancreatic Cancer Risk.
Read at PubMed Central
PubMed Central · Sep 1, 2026
CPT1A through succinylation regulates the CTCF/LINC01503‒91aa feedback loop to promote gemcitabine resistance in pancreatic ductal adenocarcinoma.
Read at PubMed Central
PubMed Central · Sep 1, 2026
Targeting PRMT5 Inhibitor-Induced Adaptation in Pancreatic Cancer with the RBM39 Degrader Indisulam.
Read at PubMed Central
PubMed Central · Aug 31, 2026
Single-cell RNA sequencing uncovers an immunosuppressive program in PDAC mast cells: tumour-driven activation, proliferation, and association with Treg recruitment.
Read at PubMed Central
PubMed Central · Aug 28, 2026
Current burden, incidence trends, and future projections of pancreatic cancer in adults worldwide.
Read at PubMed Central
PubMed Central · Aug 27, 2026
Surgical outcomes from nationwide implementation of the international best practice for locally advanced pancreatic cancer (PREOPANC-4) study.
Read at PubMed Central
PubMed Central · Aug 27, 2026
Intraoperative esketamine for postoperative analgesia and depression in pancreatic cancer surgery: protocol for a multicenter randomized controlled trial.
Read at PubMed Central
U.S. Food and Drug Administration · Aug 26, 2026
FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer
The U.S. Food and Drug Administration today approved Rasonque (daraxonrasib), a RAS inhibitor for the most common form of pancreatic cancer—delivering a new treatment option to patients with advanced pancreatic cancer months ahead of schedule.
View original at U.S. Food and Drug Administration
PubMed Central · Aug 26, 2026
Myoferlin at the crossroad of vesicle trafficking and mitochondrial function: implications for pancreatic cancer progression and stromal reprogramming.
Read at PubMed Central

pancreatic cancer

FDA-approved treatments

Prevalence

Tests / detection method

Therapeutic pipeline

Recent news for pancreatic cancer

Clinical Impact of the C-Reactive Protein-Albumin-Lymphocyte Index as a Prognostic Biomarker in Patients With Recurrent Pancreatic Cancer.

Perioperative Nutritional Changes Predict Adjuvant S-1 Dose Intensity in Resectable Pancreatic Cancer.

Synthetic long peptide and DNA personalized cancer vaccines induce robust neoantigen-specific T cell responses in pancreatic cancer.

[(177)Lu]Lu-AKIR001 for CD44v6-Positive Pancreatic Cancer: Preclinical Efficacy and Combination Strategies.

KRAS is required for plexiform neurofibroma formation and represents a targetable vulnerability in established tumors.

Multinucleated Giant Cells in Human Pancreatic Cancer Are a Distinct Macrophage Population Undergoing a DNA Damage Response and Associated with an Aggressive Tumor Microenvironment.

KRAS Inhibitor-Induced Cancer Cell Death Enhances Sensitivity to Immune-Mediated Bystander Killing of Drug-Resistant Subclones.

Aerobic Exercise Activates S1PR1 Signaling in Tumor Endothelial Cells to Promote Vascular Function in Pancreatic Cancer.

The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial.

Cardiovascular-Kidney-Metabolic Syndrome Severity and Risk of Pancreatic Cancer in a Large Prospective Cohort.

Dietary-Derived Corchorus olitorius L. Extract Suppresses KRAS-Mutant Pancreatic Cancer by Activating Ferritinophagy-Dependent Ferroptosis.

Artificial Intelligence-Estimated Intrapancreatic Fat and Its Relationship to Familial and Germline Pancreatic Cancer Risk.

CPT1A through succinylation regulates the CTCF/LINC01503‒91aa feedback loop to promote gemcitabine resistance in pancreatic ductal adenocarcinoma.

Targeting PRMT5 Inhibitor-Induced Adaptation in Pancreatic Cancer with the RBM39 Degrader Indisulam.

Single-cell RNA sequencing uncovers an immunosuppressive program in PDAC mast cells: tumour-driven activation, proliferation, and association with Treg recruitment.

Current burden, incidence trends, and future projections of pancreatic cancer in adults worldwide.

Surgical outcomes from nationwide implementation of the international best practice for locally advanced pancreatic cancer (PREOPANC-4) study.

Intraoperative esketamine for postoperative analgesia and depression in pancreatic cancer surgery: protocol for a multicenter randomized controlled trial.

FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer

Myoferlin at the crossroad of vesicle trafficking and mitochondrial function: implications for pancreatic cancer progression and stromal reprogramming.